NCT02309177 is a Phase 1 clinical trial of nab-Paclitaxel in Breast Neoplasms, sponsored by Celgene.

Who is sponsoring NCT02309177?

NCT02309177 is sponsored by Celgene.

What drugs are being tested in NCT02309177?

Interventions in NCT02309177: nab-Paclitaxel, Nivolumab, Gemcitabine, Carboplatin.

What condition does NCT02309177 study?

NCT02309177 studies Breast Neoplasms, Pancreatic Neoplasms.

Is NCT02309177 still recruiting?

NCT02309177 is currently completed. Last updated 31 May 2019.

Last reviewed 2019-05-31 · How we verify

NCT02309177

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Safety Study of Nivolumab With Nab-Paclitaxel Plus or Minus Gemcitabine in Pancreatic Cancer, Nab-Paclitaxel / Carboplatin in Stage IIIB/IV Non-Small Cell Lung Cancer or Nab-Paclitaxel in Recurrent Metastatic Breast Cancer

Completed Phase 1 Last updated 31 May 2019

What this trial tests

Phase 1 trial testing nab-Paclitaxel in Breast Neoplasms in 114 participants. Completed in 12 September 2018.

Timeline

12 January 2015

Primary endpoint
12 September 2018

12 September 2018

Quick facts

Lead sponsor	Celgene
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	114
Start date	12 January 2015
Primary completion	12 September 2018
Estimated completion	12 September 2018
Sites	15 locations across United States

Drugs / interventions tested

nab-Paclitaxel (nab-paclitaxel) — full drug profile →
Nivolumab (nivolumab) — full drug profile →
Gemcitabine (gemcitabine) — full drug profile →
Carboplatin (Carboplatin) — full drug profile →

Conditions studied

Breast Neoplasms — all drugs for Breast Neoplasms →
Pancreatic Neoplasms — all drugs for Pancreatic Neoplasms →

Sponsor

Celgene — full company profile →

Who can join

18 and older, any sex, with Breast Neoplasms or Pancreatic Neoplasms. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to assess safety of nab-paclitaxel based chemotherapy regimens administered prior to and/or in combination with nivolumab in Pancreatic Cancer, Non Small Cell Lung Cancer (NSCLC) and Metastatic Breast Cancer (mBC).

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Mechanisms of immune evasion in breast cancer.
Bates JP, Derakhshandeh R, Jones L, Webb TJ. · · 2018 · cited 206× · PMID 29751789 · DOI 10.1186/s12885-018-4441-3
Current and future immunotherapeutic approaches in pancreatic cancer treatment.
Farhangnia P, Khorramdelazad H, Nickho H, Delbandi AA. · · 2024 · cited 153× · PMID 38835055 · DOI 10.1186/s13045-024-01561-6
Immune Checkpoint Inhibition for Pancreatic Ductal Adenocarcinoma: Current Limitations and Future Options.
Kabacaoglu D, Ciecielski KJ, Ruess DA, Algül H. · · 2018 · cited 152× · PMID 30158932 · DOI 10.3389/fimmu.2018.01878
A Review of Systemic Treatment in Metastatic Triple-Negative Breast Cancer.
Zeichner SB, Terawaki H, Gogineni K. · · 2016 · cited 134× · PMID 27042088 · DOI 10.4137/bcbcr.s32783
Pancreatic cancer: optimizing treatment options, new, and emerging targeted therapies.
Chiorean EG, Coveler AL. · · 2015 · cited 133× · PMID 26185420 · DOI 10.2147/dddt.s60328
New Strategies in Breast Cancer: Immunotherapy.
Pusztai L, Karn T, Safonov A, Abu-Khalaf MM, et al · · 2016 · cited 108× · PMID 26867935 · DOI 10.1158/1078-0432.ccr-15-1315
Combinatorial approach to cancer immunotherapy: strength in numbers.
Vilgelm AE, Johnson DB, Richmond A. · · 2016 · cited 83× · PMID 27256570 · DOI 10.1189/jlb.5ri0116-013rr
Combinatorial Approach to Improve Cancer Immunotherapy: Rational Drug Design Strategy to Simultaneously Hit Multiple Targets to Kill Tumor Cells and to Activate the Immune System.
Joshi S, Durden DL. · · 2019 · cited 76× · PMID 30853982 · DOI 10.1155/2019/5245034

Verify or expand the search:

Other trials of nab-Paclitaxel

Trials testing the same drug.

NCT05064618 — Investigator-initiated Clinical Trial of MIKE-1 · Phase 1, PHASE2 · recruiting
NCT04979585 — Camrelizumab Plus Amlotinib and Chemotherapy in the First-line Treatment of Melanoma · Phase 2 · unknown
NCT04205812 — Platinum-Based Chemotherapy With/Without INCMGA00012, an Anti-PD-1 Antibody, in Non-Small Cell Lung Cancer · Phase 3 · active not recruiting
NCT04257448 — Safety and Tolerance of Epigenetic and Immunomodulating Drugs Combined With Chemotherapeutics in Patients Suffering From · Phase 1, PHASE2 · completed
NCT04066790 — Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer · Phase 2 · terminated

Other recruiting trials for Breast Neoplasms

Currently open trials in the same condition.

NCT07214532 — Signatera-Guided CDK4/6 Inhibitor Therapy in Breast Cancer · NA · recruiting
NCT07500428 — Construction of a Benchmark for Breast Ultrasound AI Interpretation and Performance Evaluation of Multimodal AI Models · recruiting
NCT07581834 — Efficacy and Safety of Dalpiciclib Combined With Endocrine Adjuvant Therapy for Early HR +/HER2- Breast Cancer: a Multic · Phase 2 · recruiting
NCT07222215 — PhII Randomized CAPecitabine + ELAcestrant vs. Capecitabine Alone in ER+ Breast Cancer (CAPELA) · Phase 2 · recruiting
NCT07465393 — Facility-Based Multi-Modal Rehab vs. Home-Based Resistance Exercise for Quality of Life in Breast Cancer Survivors · NA · recruiting

Other Celgene trials

Trials by the same sponsor.

NCT07242781 — A Study to Evaluate the Effect of Itraconazole and Rifampin on the Drug Levels of AR-LDD (BMS-986365) in Healthy Adult M · Phase 1 · recruiting
NCT06988488 — A Study to Determine the Recommended Dose and Schedule, and Evaluate the Safety and Preliminary Efficacy of Mezigdomide · Phase 1, PHASE2 · recruiting
NCT06911502 — A Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator's Ch · Phase 3 · recruiting
NCT06808984 — Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986368, for the Treatment of Agitation in Participants W · Phase 2 · recruiting
NCT06782490 — A Study to Evaluate the Efficacy, Safety and Tolerability of BMS-986368 in Participants With Multiple Sclerosis Spastici · Phase 2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02309177 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Celgene
Last refreshed: 31 May 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02309177.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing